4-ethyl-N,N-dimethylpiperazine-1-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-ethyl-N,N-dimethylpiperazine-1-carboxamide
• 化学式: C₉H₁₉N₃O
• mdl: MFCD05691071
• 分子量: 185.27
• InChiKey: ZZVSGLOOBVGUQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  26.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] CARBOCYCLIC SULFONE RORγ MODULATORS<br/>[FR] COMPOSÉS SULFONE CARBOCYCLIQUE SERVANT DE MODULATEURS DE RORΓ
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015103508A1

  公开（公告）日：2015-07-09

  Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其立体异构体、互变异构体、药学上可接受的盐、溶剂化物或前药，其中所有取代基在此处定义。还提供了包含这些化合物的药物组合物。这些化合物和组合物在调节细胞中的RORγ活性的方法以及治疗患有疾病或紊乱的受试者的方法中是有用的，其中受试者在调节RORγ活性方面会从中获益，例如自身免疫和/或炎症性疾病。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017011776A1

  公开（公告）日：2017-01-19

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
  申请人：Li Xiaoming

  公开号：US20080194545A1

  公开（公告）日：2008-08-14

  The present invention is directed to compounds of formula I, pharmaceutical compositions comprising the compounds, and methods for making and using the inventive compounds.

  本发明涉及式I的化合物，包括该化合物的药物组合物，以及制备和使用该创新化合物的方法。
• Carbamate compounds as 5-HT4 receptor agonists
  申请人：Long D. Daniel

  公开号：US20080090811A1

  公开（公告）日：2008-04-17

  The invention provides novel benzoimidazolone-carboxamide-derived carbamate 5-HT 4 receptor agonist compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , a, and b are defined in the disclosure. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT 4 receptor activity, and processes and intermediates useful for preparing such compounds.

  本发明提供了一种新颖的苯并咪唑酮-羧酰胺衍生的碳酸酯5-HT4受体激动剂化合物，其化学式为(I)，其中R1、R2、R3、R4、a和b在本申请中有定义。本发明还提供了包含这些化合物的制药组合物，使用这些化合物治疗与5-HT4受体活性相关的疾病的方法，以及用于制备这些化合物的过程和中间体。
• NOVEL TRIAZINE COMPOUNDS
  申请人：Dugar Sundeep

  公开号：US20130303516A1

  公开（公告）日：2013-11-14

  The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/or the mTOR pathway.

  本发明涉及公式（1）的新型三嗪类化合物，其制备方法、含有这些化合物的药物组合物以及使用这些化合物治疗增殖性疾病，如肿瘤和癌症，以及与PI3激酶、PI3激酶途径、mTOR和/或mTOR途径失调相关或相关的其他状况和疾病。